This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gross, R. D. Articles by Lindsay, R. N. Search for Related Content PubMed PubMed Citation Articles by Gross, R. D. Articles by Lindsay, R. N. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Antibiotics Pinkeye Hazardous Substances DB CIPROFLOXACIN TOBRAMYCIN Social Bookmarking                   What's this?

A Comparison of Ciprofloxacin and Tobramycin in Bacterial Conjunctivtis in Children

Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas

Robert O. Hoffman, MD

John Moran Eye Center, University of Utah, Salt Lake City, Utah

Rob N. Lindsay, MD

Intermountain Pediatric Clinic, Inc., Salt Lake City, Utah

A study was conducted to determine the safety and efficacy of topically applied ciprofloxacin ophthalmic solution in a pediatric population experiencing acute bacterial conjunctivitis. Topically applied ciprofloxacin (3mg/mL) is known to be a safe and effective treatment for adults suffering from bacterial conjunctivitis; however, the safety and effectiveness of this broad-spectrum fluoroquinolone in pediatric patients is not well established. Ciprofloxacin was evaluated in a double-blind, randomized, controlled study of 257 patients ranging from 0 (i.e., less than 1 year) to 12 years of age from 33 geographically diverse medical centers. The children received either 0.3% ciprofloxacin ophthalmic solution (Ciloxan^TM, Alcon Laboratories, Fort Worth, TX) or tobramycin ophthalmic solution (Tobrex^TM, Alcon Laboratories, Fort Worth, TX). Both test medications were administered topically every 2 hours on days 1 and 2 followed by every 4 hours on days 3 through 7. Eyes were cultured prior to enrollment and again on day 7. Treatment efficacy as determined by microbiological culture data and physicians' judgment of overall resolution was similar for the ciprofloxacin and tobramycin groups. Microbiological eradication was observed in 90.1% of the ciprofloxacin group and 84.3% of the tobramycin group (P= 0.29). Physicians judged 87.0% of the ciprofloxacin patients and 89.9% of the tobramycin patients clinically cured on day 7 (P>0.5) There were no serious adverse medical events attributable to either treatment. This study showed that topically applied ciprofloxacin ophthalmic solution is safe and effective in a pediatric population experiencing acute bacterial conjunctivitis.

Clinical Pediatrics, Vol. 36, No. 8, 435-444 (1997)
DOI: 10.1177/000992289703600801


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C Ferrer, A Rodriguez, J L Abad, J Fernandez, and J L Alio Bactericidal effect of intravitreal levofloxacin in an experimental model of endophthalmitis Br. J. Ophthalmol., May 1, 2008; 92(5): 678 - 682. [Abstract] [Full Text] [PDF]

				I. Cochereau, A. Meddeb-Ouertani, M. Khairallah, A. Amraoui, K. Zaghloul, M. Pop, L. Delval, P. Pouliquen, R. Tandon, P. Garg, et al. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children Br. J. Ophthalmol., April 1, 2007; 91(4): 465 - 469. [Abstract] [Full Text] [PDF]

				S. L. Block, J. Hedrick, R. Tyler, A. Smith, R. Findlay, E. Keegan, and D. W. Stroman Increasing Bacterial Resistance in Pediatric Acute Conjunctivitis (1997-1998) Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1650 - 1654. [Abstract] [Full Text]

				D. K. Wallace and P. G. Steinkuller Ocular Medications in Children Clinical Pediatrics, November 1, 1998; 37(11): 645 - 652. [Abstract] [PDF]